OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
Adam J. Nelson, Neha J. Pagidipati, Vanita R. Aroda, et al.
Circulation (2021) Vol. 144, Iss. 1, pp. 74-84
Open Access | Times Cited: 55
Adam J. Nelson, Neha J. Pagidipati, Vanita R. Aroda, et al.
Circulation (2021) Vol. 144, Iss. 1, pp. 74-84
Open Access | Times Cited: 55
Showing 1-25 of 55 citing articles:
Development and Validation of the American Heart Association’s PREVENT Equations
Sadiya S. Khan, Kunihiro Matsushita, Yingying Sang, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 430-449
Closed Access | Times Cited: 216
Sadiya S. Khan, Kunihiro Matsushita, Yingying Sang, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 430-449
Closed Access | Times Cited: 216
Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 169
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 169
Ten things to know about ten cardiovascular disease risk factors – 2022
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 79
Harold Bays, Anandita Agarwala, Charles German, et al.
American Journal of Preventive Cardiology (2022) Vol. 10, pp. 100342-100342
Open Access | Times Cited: 79
Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes
Teresa Vilariño‐García, María Polonio-González, Antonio Pérez‐Pérez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2338-2338
Open Access | Times Cited: 60
Teresa Vilariño‐García, María Polonio-González, Antonio Pérez‐Pérez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2338-2338
Open Access | Times Cited: 60
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Michelle D. Kelsey, Adam J. Nelson, Jennifer B. Green, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 18, pp. 1849-1857
Open Access | Times Cited: 67
Michelle D. Kelsey, Adam J. Nelson, Jennifer B. Green, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 18, pp. 1849-1857
Open Access | Times Cited: 67
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
Adam J. Nelson, Emily C. O’Brien, Lisa A. Kaltenbach, et al.
JAMA Network Open (2022) Vol. 5, Iss. 2, pp. e2148030-e2148030
Open Access | Times Cited: 56
Adam J. Nelson, Emily C. O’Brien, Lisa A. Kaltenbach, et al.
JAMA Network Open (2022) Vol. 5, Iss. 2, pp. e2148030-e2148030
Open Access | Times Cited: 56
Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease
Aya Ozaki, Dennis T. Ko, Alice Chong, et al.
CMAJ Open (2023) Vol. 11, Iss. 3, pp. E494-E503
Open Access | Times Cited: 24
Aya Ozaki, Dennis T. Ko, Alice Chong, et al.
CMAJ Open (2023) Vol. 11, Iss. 3, pp. E494-E503
Open Access | Times Cited: 24
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
JAMA Neurology (2025)
Closed Access | Times Cited: 1
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
JAMA Neurology (2025)
Closed Access | Times Cited: 1
Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway
Shaohan Huang, Beibei Wu, Yingzi He, et al.
Hepatology Communications (2023) Vol. 7, Iss. 3, pp. e0045-e0045
Open Access | Times Cited: 21
Shaohan Huang, Beibei Wu, Yingzi He, et al.
Hepatology Communications (2023) Vol. 7, Iss. 3, pp. e0045-e0045
Open Access | Times Cited: 21
Prioritizing Patient Experiences in the Management of Diabetes and Its Complications: An Endocrine Society Position Statement
Rita R. Kalyani, Myriam Allende-Vigo, Kellie Antinori-Lent, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 5, pp. 1155-1178
Open Access | Times Cited: 5
Rita R. Kalyani, Myriam Allende-Vigo, Kellie Antinori-Lent, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 5, pp. 1155-1178
Open Access | Times Cited: 5
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway
Xiayun Ni, Xiaojun Feng, Zhihua Wang, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1604-1617
Closed Access | Times Cited: 5
Xiayun Ni, Xiaojun Feng, Zhihua Wang, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1604-1617
Closed Access | Times Cited: 5
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
Once‐weekly glucagon‐like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial)
Jilin Li, Yu Tian, Liping Li, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Jilin Li, Yu Tian, Liping Li, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence
Josiah Moore, Ndidi Iheme, Nicholas Rebold, et al.
Pharmacy (2025) Vol. 13, Iss. 2, pp. 46-46
Open Access
Josiah Moore, Ndidi Iheme, Nicholas Rebold, et al.
Pharmacy (2025) Vol. 13, Iss. 2, pp. 46-46
Open Access
Effect of Hypoglycemic Drugs on Patients with Heart Failure with or without T2DM: A Bayesian Network Meta-analysis
Zhaolun Zhang, Su‐Hsun Liu, Jiawen Xian, et al.
Reviews in Cardiovascular Medicine (2025) Vol. 26, Iss. 3
Open Access
Zhaolun Zhang, Su‐Hsun Liu, Jiawen Xian, et al.
Reviews in Cardiovascular Medicine (2025) Vol. 26, Iss. 3
Open Access
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma
Anqi Zhang, Xincheng Zhang, Aige Yang, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 3, pp. 946-965
Closed Access
Anqi Zhang, Xincheng Zhang, Aige Yang, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 3, pp. 946-965
Closed Access
The management of cardiovascular risk in people with diabetes: Insights from an audit of health services providing diabetes care
Ella Zomer, Stella Talic, Ahmad Reza Pourghaderi, et al.
Diabetes Research and Clinical Practice (2025), pp. 112121-112121
Closed Access
Ella Zomer, Stella Talic, Ahmad Reza Pourghaderi, et al.
Diabetes Research and Clinical Practice (2025), pp. 112121-112121
Closed Access
Evidence-Based SGLT2 Inhibitor and GLP-1 Receptor Agonist Use by Race in the VA Healthcare System
Demetria M. Bolden, Vanessa Richardson, Taufiq Salahuddin, et al.
American Journal of Preventive Cardiology (2025), pp. 100966-100966
Open Access
Demetria M. Bolden, Vanessa Richardson, Taufiq Salahuddin, et al.
American Journal of Preventive Cardiology (2025), pp. 100966-100966
Open Access
Glycated hemoglobin and body mass index as mediators of GLP‐1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 4
Open Access
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 4
Open Access
Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes
Saiyang Xie, Min Zhang, Wenke Shi, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 19
Open Access | Times Cited: 18
Saiyang Xie, Min Zhang, Wenke Shi, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 19
Open Access | Times Cited: 18
Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder
Rahul N. Patel, Akash Sharma, Anand Prasad, et al.
Kidney Medicine (2023) Vol. 5, Iss. 12, pp. 100705-100705
Open Access | Times Cited: 9
Rahul N. Patel, Akash Sharma, Anand Prasad, et al.
Kidney Medicine (2023) Vol. 5, Iss. 12, pp. 100705-100705
Open Access | Times Cited: 9
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease
André Scheen
Diabetes Epidemiology and Management (2024) Vol. 14, pp. 100197-100197
Open Access | Times Cited: 3
André Scheen
Diabetes Epidemiology and Management (2024) Vol. 14, pp. 100197-100197
Open Access | Times Cited: 3
The Final Frontier in Diabetes Care: Implementing Research in Real-World Practice
Jennifer B. Green, Matthew J. Crowley, Thirunavukkarasu Sathish, et al.
Diabetes Care (2024)
Open Access | Times Cited: 3
Jennifer B. Green, Matthew J. Crowley, Thirunavukkarasu Sathish, et al.
Diabetes Care (2024)
Open Access | Times Cited: 3
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 8
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 8
